Solta Medical, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Solta Medical, Inc.
The 14 biopharma firms that went public during the first half of the year generated a 25% average return, helped by an outlier whose value rose 585%. Excluding Belite Bio, the -18% return for the IPO class of 2022 is more representative of current market realities.
With its IPO of Bausch + Lomb bringing in $630m in proceeds, Bausch Health is moving forward with its plan to use the eye care unit’s separation to pay down its remaining debt.
Bausch Health is paying down its debt with a $630m IPO for its Bausch + Lomb eyecare product business.
Daily notebook from the virtual J.P. Morgan Healthcare Conference: new immunotherapies coming, what the year could look like in deals and new updates from multiple Asian companies.
- Medical Devices